» Articles » PMID: 38929522

Epigenetics in Glaucoma

Abstract

Primary open angle glaucoma (POAG) is defined as a "genetically complex trait", where modifying factors act on a genetic predisposing background. For the majority of glaucomatous conditions, DNA variants are not sufficient to explain pathogenesis. Some genes are clearly underlying the more "Mendelian" forms, while a growing number of related polymorphisms in other genes have been identified in recent years. Environmental, dietary, or biological factors are known to influence the development of the condition, but interactions between these factors and the genetic background are poorly understood. Several studies conducted in recent years have led to evidence that epigenetics, that is, changes in the pattern of gene expression without any changes in the DNA sequence, appear to be the missing link. Different epigenetic mechanisms have been proven to lead to glaucomatous changes in the eye, principally DNA methylation, post-translational histone modification, and RNA-associated gene regulation by non-coding RNAs. The aim of this work is to define the principal epigenetic actors in glaucoma pathogenesis. The identification of such mechanisms could potentially lead to new perspectives on therapeutic strategies.

Citing Articles

Insights on the Genetic and Phenotypic Complexities of Optic Neuropathies.

DEsposito F, Zeppieri M, Cordeiro M, Capobianco M, Avitabile A, Gagliano G Genes (Basel). 2025; 15(12.

PMID: 39766826 PMC: 11675667. DOI: 10.3390/genes15121559.


Candidate SNP Markers Significantly Altering the Affinity of the TATA-Binding Protein for the Promoters of Human Genes Associated with Primary Open-Angle Glaucoma.

Zolotareva K, Dotsenko P, Podkolodnyy N, Ivanov R, Makarova A, Chadaeva I Int J Mol Sci. 2024; 25(23).

PMID: 39684516 PMC: 11641052. DOI: 10.3390/ijms252312802.


Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS.

Toader C, Tataru C, Munteanu O, Serban M, Covache-Busuioc R, Ciurea A Int J Mol Sci. 2024; 25(23.

PMID: 39684324 PMC: 11641752. DOI: 10.3390/ijms252312613.


Impact of COVID-19 pandemic on ocular disease: KNHANES 2015-2021.

Kim H, Ryu Y, Shin Y Sci Rep. 2024; 14(1):20706.

PMID: 39237530 PMC: 11377421. DOI: 10.1038/s41598-024-70767-y.

References
1.
Wang F, Zhang C, Maminishkis A, Dong L, Zhi C, Li R . MicroRNA-204/211 alters epithelial physiology. FASEB J. 2010; 24(5):1552-71. PMC: 3231816. DOI: 10.1096/fj.08-125856. View

2.
Tribble J, Kastanaki E, Uslular A, Rutigliani C, Enz T, Williams P . Valproic Acid Reduces Neuroinflammation to Provide Retinal Ganglion Cell Neuroprotection in the Retina Axotomy Model. Front Cell Dev Biol. 2022; 10:903436. PMC: 9135180. DOI: 10.3389/fcell.2022.903436. View

3.
Evangelho K, Mogilevskaya M, Losada-Barragan M, Vargas-Sanchez J . Pathophysiology of primary open-angle glaucoma from a neuroinflammatory and neurotoxicity perspective: a review of the literature. Int Ophthalmol. 2018; 39(1):259-271. DOI: 10.1007/s10792-017-0795-9. View

4.
Pelzel H, Schlamp C, Waclawski M, Shaw M, Nickells R . Silencing of Fem1cR3 gene expression in the DBA/2J mouse precedes retinal ganglion cell death and is associated with histone deacetylase activity. Invest Ophthalmol Vis Sci. 2012; 53(3):1428-35. PMC: 3339913. DOI: 10.1167/iovs.11-8872. View

5.
Schmitt H, Grosser J, Schlamp C, Nickells R . Targeting HDAC3 in the DBA/2J spontaneous mouse model of glaucoma. Exp Eye Res. 2020; 200:108244. PMC: 8344090. DOI: 10.1016/j.exer.2020.108244. View